RxDoctor Payments Data

Stephen Carriere

Urology · New Orleans, LANPI 1942628086

Payments from drug & device makers

$3,316in general payments, 2019–2025

Across 116 payments — averaging $28.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$497
  • Astellas Pharma US Inc$351
  • Pfizer$313
  • Cook Medical LLC$310
  • Sumitomo Pharma America, Inc.$250
  • Medtronic$182
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$3,316100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,316 in reported general payments places this provider in the 50th percentile of 199 urology providers in Louisiana.

See all urology providers in Louisiana

Medicare billing

Part B allowed, 2024
$59,507
Medicare patients
221
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron205$122,474
GemtesaVibegron63$37,290
Mirabegron ErMirabegron14$6,416
LinzessLinaclotide12$6,137
Solifenacin Succinate79$3,647
Tamsulosin Hcl267$2,383
Tolterodine Tartrate ErTolterodine Tartrate38$2,267
Oxybutynin Chloride ErOxybutynin Chloride147$1,794
Testosterone12$1,703
Estradiol22$1,522
Finasteride163$1,326
Testosterone Cypionate19$779
Doxycycline Monohydrate34$761
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav48$536
Alfuzosin Hcl ErAlfuzosin Hcl22$532

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$351$122,474205 claims
Sumitomo Pharma America, Inc.Gemtesa$250$37,29063 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 199 urology providers in Louisiana.

Other urology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →